Pamela Szeeley, MD
Psychiatry · Camden, NJNPI 1043305808
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 25.0% of the total. Reporting peaked in 2019 at $1,375 and has fallen 89.7% since, to $141 in 2025. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$598
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$377
- Neurocrine Biosciences, Inc.$258
- Alkermes, Inc.$208
- plus $648 from 10 others
What the payments were for
- Food & beverage$3,93595%
- Education$2155%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 53 | $1,037 |
| Teva Pharmaceuticals USA, Inc. | 30 | $1,024 |
| AbbVie(2 entities) | 22 | $598 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $377 |
| Neurocrine Biosciences, Inc. | 19 | $258 |
| Alkermes, Inc. | 6 | $208 |
| Otsuka America Pharmaceutical, Inc. | 11 | $170 |
| Johnson & Johnson | 11 | $166 |
| Indivior Inc. | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Vanda Pharmaceuticals Inc. | 4 | $55 |
| Lundbeck LLC | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Tris Pharma Inc | 2 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,150 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $98,651 |
| Invega SustennaPaliperidone Palmitate | 53 | $92,783 |
| Abilify MaintenaAripiprazole | 15 | $38,148 |
| Lurasidone Hcl | 42 | $23,621 |
| VraylarCariprazine Hcl | 14 | $22,550 |
| TrintellixVortioxetine Hydrobromide | 26 | $21,527 |
| Duloxetine Hcl | 199 | $6,209 |
| Aripiprazole | 75 | $6,011 |
| Bupropion XlBupropion Hcl | 156 | $4,234 |
| Quetiapine Fumarate | 339 | $3,980 |
| Divalproex Sodium | 83 | $3,494 |
| Buspirone Hcl | 183 | $3,022 |
| Mirtazapine | 213 | $2,972 |
| Clonidine Hcl ErClonidine Hcl | 11 | $2,903 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $2,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $258 | $98,65112 claims |
| Johnson & JohnsonInvega Sustenna | $166 | $92,78353 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $170 | $38,14815 claims |
| AbbVieVraylar | $598 | $22,55014 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $63 | $21,52726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Camden
- Anthony RostainCamden$110K
- Venitius NunezCamden$16K
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Gary SmallHackensack$170K
- Shankar SrinivasanParsippany$155K
- Matthew PiteraToms River$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.